Research summary, original research, 2016

Introduction Of A Team Based Approach To Radiation Dose Reduction In The Enhancement Of The Overall Radiation Safety Profile Of FEVAR

Rolls AE, Rosen S, Constantinou J, Davis M, Cole J, Desai M, et al.. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2016

Read the original paper

In plain language

At one fenestrated endovascular aneurysm repair (FEVAR) centre, introducing fusion imaging with a team-based radiation safety approach was associated with lower patient skin dose, lower dose-area product (DAP) and shorter procedures. Staff dose was not measured, though lower patient dose generally means less scatter.

At a glance

Type of study
Original research, Retrospective cohort study
Who was studied
Patients, Vascular surgeons
Size
n = 42 patients
Summary based on
the abstract

What it found

  • Air kerma (skin dose) was lower after the team-based, fusion-guided approach was introduced.

    Key figures: Modern 1.6 Gy (IQR 1.09-2.1) vs Historic 4.4 Gy (3.2-7.05), p<0.001

  • Dose-area product was lower in the Modern group.

    Key figures: 159 Gy.cm2 (IQR 123-226) vs 264.93 Gy.cm2 (173.3-366.8), p=0.006

  • Procedure time fell substantially in the Modern group.

    Key figures: median 285 min (IQR 268-322) vs 450 min (IQR 360-540), p<0.001

  • Fluoroscopy time and renal function did not differ between groups.

Limits to keep in mind

Small single-centre before-after comparison (21 vs 21 patients) with historic controls; only patient dose metrics were reported, with no staff dosimetry, and structured dose reports such as frame-rate changes were unavailable.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.